RA
HTGM

Royce & Associates’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Royce & Associates’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,656
Closed -$794K – 1199
2019
Q2 		$794K Buy
+2,656
New +$1.11M 0.01% 858

Other funds holding HTGM

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Royce & Associates's HTGM Position: Q3 2019 in Review

Royce & Associates sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2019, closing a stake of 2,656 shares — an estimated $794K sold.

Royce & Associates first reported a position in HTGM in Q2 2019 and held it in 1 quarter. The position peaked at $794K in Q2 2019. 44 funds tracked by Wall St. Rank hold HTGM as of Q3 2019.

  • Royce & Associates reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Royce & Associates sold 2,656 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2019, an estimated $794K.
  • Royce & Associates first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Royce & Associates's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $794K in Q2 2019.
  • 44 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2019.

Based on Royce & Associates's 13F filing for Q3 2019, filed 13 Nov 2019.